ReviewCurrent oncology reports2019
The Evolution of Adjuvant Therapy for Melanoma.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Exploring the causal relationship between immune cell characteristics and melanoma: A two-way Mendelian randomization study.Medicine · 2025Article
- Molecular characteristics and therapeutic implications of Toll-like receptor signaling pathway in melanoma.Scientific reports · 2023Article
- Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.Cancers · 2023Review
- New Treatment Horizons in Uveal and Cutaneous Melanoma.Life (Basel, Switzerland) · 2023Review
- Cytotoxicity Induced by Newly Synthesized Palladium (II) Complexes Lead to the Death of MCF-7 and MDA-MB-435 Cancer Cell Lines.Advanced pharmaceutical bulletin · 2023Article
- Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases.Acta dermato-venereologica · 2022Article
- Novel natural inhibitors targeting B-RAF(V600E) by computational study.Bioengineered · 2021Article
- Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.Cancer medicine · 2021Article
- The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.Targeted oncology · 2021Review
- Characterization and Clinical Utility ofCancers · 2021Article
- Advances in Targeting Cutaneous Melanoma.Cancers · 2021Review
- Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells.The Journal of experimental medicine · 2021Article
- Integrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis.Frontiers in immunology · 2021Article
- A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe past decade has been a time of remarkable advancement in the field of adjuvant therapy for patients with resected high-risk melanoma. Here, we review the data for adjuvant melanoma and raise questions about the best choice of therapy for an individual patient. RECENT
findingsThere have been several new adjuvant approvals including immunotherapy and targeted therapy approaches. Nivolumab is approved for patients with nodal involvement or metastatic disease after resection. Pembrolizumab is approved for patients with nodal involvement after resection. In addition, the combination of dabrafenib and trametinib is approved in patients' nodal involvement after resection whose tumors harbor BRAF
Indexed as
Identifiers
31768772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.